Single-use bioprocessing is a manufacturing approach that utilizes disposable components and equipment to produce biopharmaceuticals, vaccines, and cell therapies. This approach eliminates the need for cleaning, sterilization, and validation between batches, reducing the risk of contamination and improving process efficiency.
Single-use bioprocessing systems typically include a range of disposable products, such as bioreactors, mixers, filters, chromatography columns, bags, tubing, and connectors. These components are used once and then discarded, which reduces the time and cost associated with traditional stainless-steel systems, which require cleaning and sterilization between batches.
The market for single-use bioprocessing in 2021 was worth
USD 14.83 billion, and by 2030 it will be worth USD 55.78 billion, growing at a 15.86% CAGR during the forecast period.
Single-use bioprocessing is becoming increasingly popular in the biopharmaceutical industry due to its advantages, including reduced capital investment, lower operating costs, improved process flexibility, and faster development times. The adoption of single-use bioprocessing will grow as the biopharmaceutical industry seeks to improve process efficiency and reduce costs.
Market Dynamics
Drivers
Due to the rising frequency of chronic disorders in the population, there is an increase in the demand for biopharmaceuticals, which will likely lead to an increase in the demand for single-use technologies and further fuel market development. For instance, the Food and Drug Administration reports that 14 biologics were authorized to treat different chronic illnesses in 2021. As a result, over the forecast period, it is anticipated that the growing number of biological approvals will raise the biopharmaceutical manufacturing process, increasing the use and adoption of single-use bioprocessing technologies and systems.
Additionally, the product’s low water consumption, excellent energy efficiency, small environmental impact, and low chance of contamination drive market growth. The single-use bioprocessing market is expanding due to the widespread use of big data-based machine learning in single-use systems, which helps increase product or drug yield and achieve maximum productivity and efficiency in terms of process. Many biopharmaceutical manufacturers are also adopting this technology as a mainstream strategy.
Restraints
The creation of bioprocesses and the manufacturing of biopharmaceuticals have heavily adopted single-use technology in recent years. Even though the benefits of these technologies are widely recognized, there are significant concerns regarding extractables and leachables that originate from single-use systems because of the potential harm they may cause to patients’ health and the quality of the products.
Opportunity
China and India are the two countries in the Asia-Pacific area with the highest potential markets for single-use bioprocessing systems. This is because of favorable government policies, increasing private investment, an aging population, and the presence of skilled labor in these countries. The significant investment in bio-manufacturing infrastructure is also a key factor in these sectors’ strong development potential and will provide a lot of future possibilities for the expansion of the single-use bioprocessing market.
Market Segmentation
By Product
The simple & peripheral elements segment earned the largest market share of 49.1% in 2022. It is due to ongoing product improvements and the growing importance of bioprocessing operations in the overall manufacturing process. For instance, Thermo Fisher Scientific, Inc. provides customization choices for its bioprocessing container bags and other bioprocessing tools, allowing users to add tubing and connectors.
By Workflow
In 2022, the upstream bioprocessing segment ruled the market with the highest revenue share of 57.9%. This is due to the ongoing improvements and advances in upstream bioprocessing technologies.
By End-Use
Manufacturers of biopharmaceuticals ruled the market and held the largest revenue share of 58.1% in 2022. The segment has experienced rapid development due to rising contract manufacturing and research services, as well as an increase in the commercial success of biologics in recent years. In bioprocessing operations, CROs and CMOs can provide several advantages, including scalability, flexibility, reduced need for internal infrastructure, and specialized supply channels. These benefits encourage the use of contract services and will positively impact the sector’s expansion in the near future.
Regional Analysis
In 2022, North America contributed the largest market share of nearly 34.2% due to the region’s established pharmaceutical and biomanufacturing sector and extensive R&D efforts. Similarly, the demand for single-use bioprocessing machinery is driven by a growing emphasis on vaccine production to support local efforts at disease prevention.
The Asia Pacific region will expand at the fastest rate of 16.71%. Multiple investments from numerous international businesses drive market growth. These investments help important businesses establish a presence in the area and seize untapped opportunities.
Key Players
- Merck KGaA
- Thermo Fisher Scientific
- Avantor
- Sartorius Stedim Biotech S.A.
- Danaher Corporation
- Eppendorf AG
- Corning
- Getinge AB
- Entegris
- PBS Biotech, Inc.
- CESCO Bioengineering Co. Ltd.
- Cellexus
- Distek, Inc.
- G&G Technologies
- ABEC, Inc.
- Able Corporation & Biott Corporation
- Solida Biotech GmbH
- Stobbe Pharma GmbH
- OmniBRx Biotechnologies
- Satake Chemical Equipment Mfg., Ltd.
- Celltainer Biotech
- Pierre Guerin
- Meissner Filtration Products, Inc.
- Bbi-Biotech GmbH
- Catalent
- Kuhner AG
The market for single-use bioprocessing in 2021 was worth USD 14.83 billion, and by 2030 it will be worth USD 55.78 billion, growing at a 15.86% CAGR during the forecast period. The benefits of single-use bioprocessing equipment, such as the reduced risk of cross-contamination, improved user protection, and increasing government support for biologic drug R&D, are the market’s main growth drivers.
Related Reports:
Plant-Based Milk Market Report – The global plant-based milk market will witness a robust CAGR of 15%, valued at
$35 billion in 2021, expected to appreciate and reach $123.1 billion by 2030, confirms Strategic Market Research.
